Valuation: Gilead Sciences, Inc.

Market Cap 169B 148B 136B 126B 239B 16,096B 243B 1,629B 639B 7,904B 633B 619B 27,379B P/E 2026 *
-48.1x
P/E 2027 * 17.6x
Enterprise Value 178B 156B 144B 133B 252B 16,999B 257B 1,721B 674B 8,348B 669B 654B 28,915B EV / Sales 2026 *
5.84x
EV / Sales 2027 * 5.21x
Free-Float
99.88%
Yield 2026 *
2.39%
Yield 2027 * 2.48%
1 day-0.66%
1 week+2.78%
Current month+6.79%
1 month+7.51%
3 months-5.05%
6 months+11.41%
Current year+9.92%
1 week 127.88
Extreme 127.88
137.7
1 month 121.39
Extreme 121.39
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Sell

Chief Executive Officer

-15,000 0.0012%
Jun. 14Sell

Executive/Senior Manager

-3,000 0.0002%
Jun. 14Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-2.79%+2.78%+19.15%+78.25% 169B
-0.49%+0.18%+54.53%+168.35% 1,084B
-1.27%-1.73%+65.41%+62.06% 634B
-2.08%-4.24%+31.15%+85.88% 447B
+0.18%-1.76%+29.04%+26.48% 330B
-6.22%-8.14%+28.87%+31.18% 295B
-1.27%-2.91%+27.42%+44.91% 285B
-0.93%-3.57%-27.74%-39.70% 218B
-1.32%-2.84%+22.60%+61.77% 199B
+0.75%-0.37%-5.20%-32.09% 137B
Average -1.34%+2.34%+24.52%+48.71% 379.69B
Weighted average by Cap. -1.29%+2.42%+37.23%+79.89%

Financials

2026 *2027 *
Net sales 30.47B 26.66B 24.58B 22.74B 43.17B 2,908B 43.89B 294B 115B 1,428B 114B 112B 4,947B 32.38B 28.32B 26.12B 24.17B 45.87B 3,090B 46.64B 313B 123B 1,518B 122B 119B 5,257B
Net income -3.37B -2.95B -2.72B -2.52B -4.78B -322B -4.86B -32.58B -12.77B -158B -12.66B -12.39B -548B 9.55B 8.35B 7.7B 7.13B 13.53B 911B 13.75B 92.25B 36.16B 448B 35.85B 35.07B 1,550B
Net Debt 9.46B 8.28B 7.63B 7.06B 13.4B 903B 13.63B 91.39B 35.83B 443B 35.51B 34.75B 1,536B -96.43M -84.36M -77.79M -71.98M -137M -9.2B -139M -932M -365M -4.52B -362M -354M -15.66B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-09 $134.82 -0.74% 3,795,935
26-07-08 $135.82 -0.40% 8,454,142
26-07-07 $136.36 +5.21% 9,177,296
26-07-06 $129.61 -1.26% 10,729,369
26-07-02 $131.27 +4.21% 8,088,800
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
135.82USD
Average target price
158.30USD
Spread / Average Target
+16.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock